Resverlogix Corp. RVX.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · resverlogix.com
Resverlogix Corp. is a late-stage clinical biotechnology company pioneering epigenetic drug development, with its lead candidate apabetalone (RVX-208) being a selective bromodomain and extra-terminal (BET) inhibitor. The company is developing apabetalone for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, and post-COVID conditions, with headquarters in Calgary, Canada.
Key ratios
ReturnOnAssets TTM -0.39
ReturnOnAssets 2024 -0.41
ReturnOnAssets 2023 -0.44
ReturnOnAssets 2022 -0.79
Recent news
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
2026-06-25 · Investing News Network
Resverlogix Closes US$2 Million Shares-for-Interest Private Placement
2026-05-19 · Investing News Network